- Home
- GLPG vs SVV Comparison
GLPG vs SVV Comparison
Compare GLPG & SVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SVV
- Stock Information
- Founded
- GLPG 1999
- SVV 1954
- Country
- GLPG Belgium
- SVV United States
- Employees
- GLPG N/A
- SVV 22700
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SVV Other Specialty Stores
- Sector
- GLPG Health Care
- SVV Consumer Discretionary
- Exchange
- GLPG Nasdaq
- SVV Nasdaq
- Market Cap
- GLPG 2.1B
- SVV 2.0B
- IPO Year
- GLPG 2005
- SVV 2023
- Fundamental
- Price
- GLPG $34.50
- SVV $12.82
- Analyst Decision
- GLPG Sell
- SVV Buy
- Analyst Count
- GLPG 3
- SVV 6
- Target Price
- GLPG $26.00
- SVV $12.20
- AVG Volume (30 Days)
- GLPG 203.5K
- SVV 2.1M
- Earning Date
- GLPG 10-29-2025
- SVV 11-06-2025
- Dividend Yield
- GLPG N/A
- SVV N/A
- EPS Growth
- GLPG N/A
- SVV N/A
- EPS
- GLPG N/A
- SVV 0.20
- Revenue
- GLPG $323,674,692.00
- SVV $1,584,135,000.00
- Revenue This Year
- GLPG $1.77
- SVV $10.04
- Revenue Next Year
- GLPG $0.44
- SVV $7.09
- P/E Ratio
- GLPG N/A
- SVV $64.78
- Revenue Growth
- GLPG 5.43
- SVV 4.47
- 52 Week Low
- GLPG $22.36
- SVV $6.48
- 52 Week High
- GLPG $37.78
- SVV $13.89
- Technical
- Relative Strength Index (RSI)
- GLPG 54.01
- SVV 53.95
- Support Level
- GLPG $32.37
- SVV $12.54
- Resistance Level
- GLPG $37.78
- SVV $13.67
- Average True Range (ATR)
- GLPG 0.77
- SVV 0.49
- MACD
- GLPG 0.00
- SVV -0.10
- Stochastic Oscillator
- GLPG 39.93
- SVV 39.72
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SVV Savers Value Village Inc.
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, merchandise, and sells these items in its stores.